Key points are not available for this paper at this time.
Abstract Introduction In the current American Joint Committee on Cancer staging system, patients with pelvic nodal metastases are considered stage IV prostate cancer. This study aims to investigate whether men with prostate‐specific membrane antigen positron emission tomography (PSMA PET)‐detected pelvic node‐positive prostate cancer at diagnosis have a better outcome compared to men with node‐positive disease identified on conventional imaging. Methods This is a retrospective cohort study comparing the outcomes of men with node‐positive prostate cancer and disease confined to the pelvis, staged with conventional versus PSMA PET imaging. Men had to be treated definitively with a combination of androgen deprivation therapy and radiation treatment to the prostate and pelvic lymph nodes. Kaplan–Meier and Cox regression analysis was used to compare biochemical failure‐free survival (BFFS) and overall survival (OS). Results Seventy‐six men with nodal metastases confined to the pelvis were identified. Fifty‐one were detected with PSMA PET while 25 were staged with conventional imaging. PSMA PET staged patients had a lower proportion of Gleason 8–10 disease (78% vs. 96%) as well as a lower median prostate‐specific antigen (11 ng/mL vs. 26 ng/mL). BFFS at 4 years was 72% with PSMA PET‐detected node‐positive disease vs. 38% with conventionally detected node‐positive disease. Four‐year OS was 93% with PSMA PET staged patients vs. 76% with conventionally staged patients. On multivariate analysis, the PSMA PET staged group was associated with improved BFFS (Adjusted HR = 3.00, 95% CI 1.43, 6.29, P = 0.004) and OS (Adjusted HR = 5.81, 95% CI 1.43, 23.7, P = 0.007). Conclusion Men with PSMA PET‐detected node‐positive prostate cancer confined to the pelvis have significantly better biochemical control and survival compared to those with node‐positive pelvic disease identified through conventional staging.
Leow et al. (Mon,) studied this question.